BACKGROUND: The ALSYMPCA trial of α-emitter Ra-223 in symptomatic bone predominant mCRPC reported Ra-223 median overall survival (OS) of 14.9 months versus 11.3 months OS for placebo (1). Subsequently reported "real world" experience with Ra-223 in smaller mCRPC patient cohorts appeared less successful(2-3).